These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6782585)

  • 1. Vaccination trials against S. mansoni and T. cruzi in experimental animals.
    Schwick HG; Hungerer KD; Zwisler O
    Prog Clin Biol Res; 1980; 47():229-40. PubMed ID: 6782585
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice.
    Basso B; Cervetta L; Moretti E; Carlier Y; Truyens C
    Vaccine; 2004 May; 22(15-16):1868-72. PubMed ID: 15121297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination against schistosomiasis.
    Smithers SR
    Prog Clin Biol Res; 1980; 47():287-99. PubMed ID: 7010375
    [No Abstract]   [Full Text] [Related]  

  • 4. [Protection of mice with Trypanosoma lewisi antigen and its fractions against experimental Trypanosoma cruzi infection].
    Fernández de Lara WG
    Rev Inst Med Trop Sao Paulo; 1972; 14(5):301-5. PubMed ID: 4630386
    [No Abstract]   [Full Text] [Related]  

  • 5. A vaccination procedure against Trypanosoma cruzi infection in mice by nonspecific immunization.
    Ortiz-Ortiz L; Gonzalez-Mendoza A; Lamoyi E
    J Immunol; 1975 Apr; 114(4):1424-5. PubMed ID: 804010
    [No Abstract]   [Full Text] [Related]  

  • 6. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.
    Haolla FA; Claser C; de Alencar BC; Tzelepis F; de Vasconcelos JR; de Oliveira G; Silvério JC; Machado AV; Lannes-Vieira J; Bruna-Romero O; Gazzinelli RT; dos Santos RR; Soares MB; Rodrigues MM
    Vaccine; 2009 Sep; 27(41):5644-53. PubMed ID: 19635607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.
    Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H
    Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of Trypanosoma rangeli against infections with a highly virulent strain of Trypanosoma cruzi.
    Zuñiga C; Palau T; Penin P; Gamallo C; de Diego JA
    Trop Med Int Health; 1997 May; 2(5):482-7. PubMed ID: 9217704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.
    Fontanella GH; De Vusser K; Laroy W; Daurelio L; Nocito AL; Revelli S; Contreras R
    Vaccine; 2008 May; 26(19):2322-34. PubMed ID: 18403070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trypanosoma cruzi: protective response of vaccinated mice is mediated by CD8+ cells, prevents signs of polyclonal T lymphocyte activation, and allows restoration of a resting immune state after challenge.
    Paiva CN; Castelo-Branco MT; Lannes-Vieira J; Gattass CR
    Exp Parasitol; 1999 Jan; 91(1):7-19. PubMed ID: 9920038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis.
    El Ridi R; Tallima H
    Vaccine; 2009 Jan; 27(5):666-73. PubMed ID: 19056448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schistosomiasis vaccines: Farewell to the God of Plague?
    Taylor MG
    J Trop Med Hyg; 1994 Oct; 97(5):257-68. PubMed ID: 7932921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization against experimental Trypanosoma cruzi infection: inherent difficulties of a uniform comparative evaluation of antigenic preparations.
    Kierszenbaum F
    Tropenmed Parasitol; 1979 Sep; 30(3):287-8. PubMed ID: 120626
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccination approaches against Trypanosoma cruzi infection.
    Cazorla SI; Frank FM; Malchiodi EL
    Expert Rev Vaccines; 2009 Jul; 8(7):921-35. PubMed ID: 19538117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of immune responses raised against Tc13 antigens of Trypanosoma cruzi in the outcome of murine experimental infection.
    García GA; Arnaiz MR; Esteva MI; Laucella SA; Garavaglia PA; Ibarra SE; Ruiz AM
    Parasitology; 2008 Mar; 135(3):347-57. PubMed ID: 17991305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trypanosoma cruzi infection from the view of CD8+ T cell immunity--an infection model for developing T cell vaccine.
    Miyahira Y
    Parasitol Int; 2008 Mar; 57(1):38-48. PubMed ID: 17728174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trypanosoma cruzi and immunoprotection: study of an attenuated strain.
    de Campanini AR; Esteva M; Laguens RP; Segura EL
    Medicina (B Aires); 1982; 42(5):502-6. PubMed ID: 6820463
    [No Abstract]   [Full Text] [Related]  

  • 18. Defect of resistance in male gerbils, Meriones unguiculatus, vaccinated with gamma-irradiated cercariae of Schistosoma mansoni against a homologous challenge infection.
    Kamiya H; Nakayama H; Yoshimura K
    J Parasitol; 1993 Aug; 79(4):616-8. PubMed ID: 8331484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of defined antigen vaccines against Schistosoma bovis and S. japonicum in bovines.
    Bashir M; Bickle Q; Bushara H; Cook L; Shi F; He D; Huggins M; Lin J; Malik K; Moloney A
    Trop Geogr Med; 1994; 46(4 Spec No):255-8. PubMed ID: 7825230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFN-gamma-dependent effector mechanisms.
    Jankovic D; Wynn TA; Kullberg MC; Hieny S; Caspar P; James S; Cheever AW; Sher A
    J Immunol; 1999 Jan; 162(1):345-51. PubMed ID: 9886405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.